ClinicalTrials.gg
CompletedNCT06800937SFINGOANNERUpdated Nov 6, 2026

Sphingolipidomic Profile in Anorexia Nervosa

An observational study in Anorexia Nervosa, sponsored by Istituto Auxologico Italiano. Completed at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Istituto Auxologico Italiano · Observational

How we know

Updated Nov 6, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
77
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Anorexia Nervosa by Istituto Auxologico Italiano — 4 open to participants now, 4 under way, none of them phase 3. Anorexia Nervosa · Istituto Auxologico Italiano.

Enrollment
4th of 15
77 · median 60
Started
2024
with 7 others
Observational
15 of 18
2 open now
Registered
13th of 18
by date

Among the 18 studies in Anorexia Nervosa by Istituto Auxologico Italiano, this one is the 4th largest by enrollment of the 15 observational ones that give a count, is one of 8 that started in 2024, is one of 15 observational ones, and was the 13th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

4 of the 18 studies in Anorexia Nervosa by Istituto Auxologico Italiano are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Anorexia Nervosa by Istituto Auxologico Italiano, or all of them as a file.
02

Study summary

: The objective of this research project will be to determine the sphingolipidomic profile in a group of women (> 18 years) affected by Anorexia Nervosa (AN), phenotypically characterized (restricting [AN-R] vs binge-eating purging [AN-BP]). Specific questionnaires will be administered for the definition of the severity of the eating disorder and depressive state (suicidality), to which will be added the evaluation of gonadal function (i.e., plasma levels of estradiol/progesterone and use of oral contraceptives).

Based on the specific lipidomic profile, which the present research project hopes to characterize, it will be possible to appropriately modify the diet of rehabilitation programs and, in the future, improve the effectiveness of the treatment itself, especially in the long term.

03

Conditions studied

  • Anorexia Nervosa

Browse trials for

Keywords

  • Anorexia nervosa
  • Sphingolipids
  • Females
  • Lipidomic profile
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

30 female adults with Anorexia nervosa, according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), hospitalized at the Division of Eating and Nutrition Disorders (END), San Giuseppe Hospital, Istituto Auxologico Italiano, IRCCS, Piancavallo, Italy.

Half will have the AN-R subtype and the other AN-BP.

30 normal weight adult women recruited from research and hospital staff, with Body Mass Index between 18.5 and 24.9 kg/m2

Eligibility criteria

Patients with Anorexia Nervosa:

Inclusion Criteria:

  • Female sex
  • Age: 18 years or older
  • Diagnosis of Anorexia Nervosa in the acute phase
  • Hospitalized at the Division of Eating and Nutrition Disorders (END), San Giuseppe Hospital, Istituto Auxologico Italiano, IRCCS, Piancavallo (VB), Italy

Exclusion Criteria:

  • Absence of signed

Control group:

Inclusion Criteria:

  • Female sex
  • Age: 18 years or older
  • between 18.5 and 24.9 kg/m2

Exclusion Criteria:

  • Absence of signed Informed Consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
77 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Anorexia Nervosa

    Adult female Anorexia Nervosa patients, hospitalized at the Division of Eating and Nutrition Disorders (END), Istituto Auxologico Italiano, IRCCS, Piancavallo (VB), Italy

    Other: Determination of sphingolipidomic profile

  • Normal weight

    Adult normal-weight women with a Body Mass Index between 18.5 and 24.9 kg/m2, recruited from research and hospital staff

    Other: Determination of sphingolipidomic profile

Interventions

  • OtherDetermination of sphingolipidomic profile

    The plasma/serum levels of the following sphingolipids will be measured: ceramides and dihydroceramides from C16 to C24, including 2 unsaturated ones (C18:1 and C24:1), sphingomyelins (those from C16 to C24 and the one C24:1), sphingosine, sphinganine, sphingosine-1-phosphate and sphinganine-1-phosphate.

06

What researchers measure

Primary outcomes

  1. Ceramides

    Plasma level of ceramide

    Time frame: Baseline

  2. Dihydroceramides

    Plasma level of dihydroceramides

    Time frame: Baseline

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2024 to primary completion in Oct 2026, 27 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jun 2026 → Oct 2026 and completion Jun 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2025
First posted
Jan 30, 2025
StartActual
Jun 19, 2024
Primary completionActual
Oct 8, 2026was Jun 2026
CompletionActual
Oct 8, 2026was Jun 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 6, 2026
Primary completion
Jun 30, 2026→Oct 8, 2026 (actual)
Nov 6, 2026
Study completion
Jun 30, 2026→Oct 8, 2026 (actual)
Nov 6, 2026
Enrollment
60 (estimated)→77 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Completed
    Primary completion Jun 30, 2026→Oct 8, 2026 (now actual)
    Study completion Jun 30, 2026→Oct 8, 2026 (now actual)
    Enrollment 60 (estimated)→77 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06800937
Responsible party
Sponsor
First posted
Jan 30, 2025
Start date
Jun 19, 2024
Primary completion
Oct 8, 2026
Completion
Oct 8, 2026
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion